Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk says diabetes drug candidate successful in phase III trials

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

The trials, which are the second and third in a series of five phase three studies in the group's ongoing LEAD programme, showed that the compound improved glucose control and lowered the body weight of the participants.

Liraglutide is a long-acting analogue of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. Studies to date show that liraglutide significantly improves glycaemic control in monotherapy and in combination therapy with metformin.

The trial results do not affect Novo Nordisk's previous financial expectations for 2007.

Novo Nordisk said it would post results from the remaining two LEAD studies in H2 2007 and Q1 2008.

Novo Nordisk's CSO, Mads Krogsgaard Thomsen, said of the data: "The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide and leave us confident that we are on track to submit for regulatory approval mid-2008."

20th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics